A phase II study of CCNU with benznidazole for metastatic malignant melanoma. 1986

N M Bleehen, and J T Roberts, and H F Newman

The response of 18 patients with metastatic malignant melanoma to the combination of CCNU (130 mg/m2) preceded 3-4 hr earlier by 20 mg/kg of the 2-nitroimidazole benznidazole has been studied. There were four partial and no complete responses in 16 patients evaluable after 1-6 courses. The median response duration was 14 wk (range 5-33) and for static disease 24 wk (range 10-54). Evidence for chemosensitization is equivocal.

UI MeSH Term Description Entries
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N M Bleehen, and J T Roberts, and H F Newman
January 1990, Medical and pediatric oncology,
N M Bleehen, and J T Roberts, and H F Newman
October 1980, Cancer,
N M Bleehen, and J T Roberts, and H F Newman
January 1981, Cancer treatment reports,
N M Bleehen, and J T Roberts, and H F Newman
January 1985, Cancer treatment reports,
N M Bleehen, and J T Roberts, and H F Newman
October 1983, American journal of clinical oncology,
N M Bleehen, and J T Roberts, and H F Newman
January 1977, Cancer treatment reports,
N M Bleehen, and J T Roberts, and H F Newman
June 1982, Cancer treatment reports,
N M Bleehen, and J T Roberts, and H F Newman
December 2004, Melanoma research,
N M Bleehen, and J T Roberts, and H F Newman
January 1981, Cancer treatment reports,
N M Bleehen, and J T Roberts, and H F Newman
November 1998, British journal of cancer,
Copied contents to your clipboard!